Good for you!
I don’t doubt the support of KOLs and that’s the only reason I am still invested in this. But that doesn’t take away the responsibility of the company towards the patients and the shareholders. And importantly not how you run a successful, thriving business.
The most basic thing they could have done in the last few years is to have good web presence, if they really were proactive and cared about these details. Also, prepare for a U.K. website. They could have hired couple of interns or consultants and gotten it done in less than $50-100k expenses in a few weeks.
Once they get U.K. approvals they can go live there with marketing, patient resources, etc on their website. But that’s too much to ask and expect from this group. As PM pointed out earlier today (in the context of the loan terms), they just seem to be lazy. On the other hand, look at Advent. They have an excellent web and social media presence.
I will also tell you from my experience in this world that these clinicians also move on at some point. You got to continue to innovate and make meaningful progress. The lure for getting involved in exciting new trials with new clinical research funding can not be dismissed!
News 
Market Data 
Discover 
AI
